AstraZeneca reveals bold ambition, looks for USD 80 billion in sales by 2030

Amid all the controversies surrounding over COVID-19 vaccine, AstraZeneca sets an ambition to achieve $80 billion in sales by 2030 and suggests significant growth aspirations for the company. According to the Chief Executive Officer, Pascal Soriot, the drug maker is planning to fasten the legacy. 

As per an official press release, the company is planning to launch 20 new medicines by 2030, many with the potential to generate more than $5 billion in peak-year revenues. To meet the specific target, the company is expecting significant growth from existing portfolios, and investment in innovation that will shape the future of medicine. 

Today we revealed a bold ambition to deliver $80bn in total revenue by 2030 ($45bn in 2023). We are set to launch 20 new medicines by 2030 as we bring patients next generation therapies. We will also halve emissions across our value chain by 2030. #AZN #WhatScienceCanDo pic.twitter.com/cONyVkejZh

— AstraZeneca (@AstraZeneca) May 21, 2024

Decoupling carbon emissions from revenue growth

The press release further says that the drug company will keep separating its rising revenue from its rising carbon emissions as it expands in all therapeutic areas. The company has already increased Total Revenue by 85% during the same period while reducing its greenhouse gas emissions (Scopes 1 and 2) by 68% from its baseline in 2015. To reach science-based net zero by 2045 at the latest, the Company plans to achieve carbon neutrality for Scope 1 and 2 emissions by 2026 and to halve its emissions for Scope 3 by 2030.

Noteworthy, this goal reflects the strategic plans of the company to expand its product portfolio, enter new markets, and potentially develop innovative therapies to address unmet medical needs.